These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Study on the sensitivity of primary tumor cells of patients with cervical cancer to chemotherapeutic combinations.
    Author: Qiu F, Zhao X.
    Journal: J BUON; 2018; 23(1):117-123. PubMed ID: 29552770.
    Abstract:
    PURPOSE: To study the sensitivity of primary tumor cells from patients with cervical cancer to frequently used chemotherapeutic combinations. METHODS: 54 samples from cervical cancer patients were collected and used to develop cell culture in vitro. Eight frequently used chemotherapeutic combinations (taxol, taxol+cisplatin, taxol+carboplatin, topotecan+cisplatin, gemcitabine+cisplatin, docetaxel, gemcitabine, cisplatin+c yclophosphamide+doxorubicin) were prepared in different concentrations [200,100,50,25, and 12.5% plasma peak concentration (PPC)] and added to tumor cell culture. Adenosine triphosphate (ATP) bioluminescence assay was used to quantify cell cytotoxicity. RESULTS: Sensitivity of primary tumor cell from patients with cervical cancer to 8 chemotherapeutic combinations were: gemcitabine < docetaxel < topotecan+cisplatin < cisplatin +cyclophosphamide+doxorubicin < gemcitabine+cisplatin < taxol < taxol+carboplatin < taxol+cisplatin. CONCLUSION: Using the drug sensitivity test to assess chemotherapeutics in the treatment of cervical cancer patients offers many benefits, being a first step to a clinically individualized chemotherapy.
    [Abstract] [Full Text] [Related] [New Search]